By Doug Macron

Amid preliminary signs that the US economy is in recovery, shares of MDRNA and Tekmira Pharmaceuticals have experienced strong gains since the beginning of the year, significantly outperforming the nearly 11 percent rise in the bellwether Nasdaq Biotechnology Index.

Not all of the public, pure-play RNAi shops have fared so well, however; both Alnylam Pharmaceuticals and RXi Pharmaceuticals have seen their stocks drop since the start of 2009.

MDRNA

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.